Claims
- 1. An antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor, wherein said antibody or antigen-binding fragment thereof inhibits binding of a ligand to said receptor, and wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.
- 2. A method of inhibiting the interaction of a cell bearing mammalian CC-chemokine receptor 1 (CCR1) with a ligand thereof, comprising contacting said cell with an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor and inhibits binding of said ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.
- 3. A method of detecting or identifying an agent which binds a mammalian CC-chemokine receptor 1 (CCR1) or ligand-binding variant thereof, comprising combining:
a) an agent to be tested; b) an antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or a ligand-binding variant thereof, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor; and c) a composition comprising a mammalian CC-chemokine receptor 1 (CCR1) or a ligand-binding variant thereof, under conditions suitable for binding of said antibody or antigen-binding fragment thereof to said mammalian CC-chemokine receptor 1 (CCR1) or ligand-binding variant thereof, and detecting or measuring binding of said antibody or antigen-binding fragment thereof to said mammalian CC-chemokine receptor 1 (CCR1) or ligand-binding variant thereof.
- 4. An antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor, wherein said antibody or antigen-binding fragment thereof inhibits binding of a ligand to the receptor with an IC50 of less than about 10 μg/ml.
- 5. An antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor with an affinity of greater than about 5×10−8 M.
- 6. A method of treating a CC-chemokine receptor 1 (CCR1)-mediated disorder in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.
- 7. A method according to claim 6, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
- 8. A method according to claim 6, wherein the ligand is a chemokine.
- 9. A method according to claim 6, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of:
a) monoclonal antibody 2D4; b) an antibody having the same epitopic specificity as monoclonal antibody 2D4; c) an antigen-binding fragment of any of (a)-(b); and d) combinations of the foregoing.
- 10. A method according to claim 6, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of:
a) a monoclonal antibody; b) a chimeric antibody; c) a human antibody; d) an antigen-binding fragment of any of (a)-(c); and e) combinations of the foregoing.
- 11. A method according to claim 6, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
- 12. A method according to claim 11, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
- 13. A method according to claim 6, wherein said antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab′ fragment and an F(ab′)2 fragment.
- 14. A method of treating a CC-chemokine receptor 1 (CCR1)-mediated disorder in a patient, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.
- 15. A method according to claim 14, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
- 16. A method according to claim 14, wherein the ligand is a chemokine.
- 17. A method of treating a patient having a disorder selected from the group consisting of an inflammatory disease, an allergy, an autoimmune disease, atherosclerosis, graft rejection and HIV infection, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof binds the second extracellular loop of said receptor.
- 18. A method according to claim 17, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
- 19. A method according to claim 17, wherein the ligand is a chemokine.
- 20. A method according to claim 17, wherein said antibody or antigen-binding fragment is selected from the group consisting of:
a) a monoclonal antibody; b) a chimeric antibody; c) a human antibody; d) an antigen-binding fragment of any of (a)-(c); and e) combinations of the foregoing.
- 21. A method according to claim 17, wherein said antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
- 22. A method according to claim 21, wherein said humanized antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 2D4.
- 23. A method of treating a patient having a disorder selected from the group consisting of an inflammatory disease, an allergy, an autoimmune disease, atherosclerosis, graft rejection and HIV infection, comprising administering to the patient an effective amount of an antibody or antigen-binding fragment thereof which binds to mammalian CC-chemokine receptor 1 (CCR1) or a portion of said receptor and inhibits binding of a ligand to the receptor, wherein said antibody or antigen-binding fragment thereof can compete with monoclonal antibody 2D4 for binding to said receptor.
- 24. A method according to claim 23, wherein said antibody or antigen-binding fragment thereof inhibits one or more functions associated with binding of the ligand to said receptor.
- 25. A method according to claim 23, wherein the ligand is a chemokine.
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser. No. 09/960,547, filed Sep. 21, 2001, which is a divisional of U.S. application Ser. No. 09/239,938, filed Jan. 29, 1999, (now U.S. Pat. No. 6,329,510). The entire teachings of the above applications are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09239938 |
Jan 1999 |
US |
Child |
09960547 |
Sep 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09960547 |
Sep 2001 |
US |
Child |
10832985 |
Apr 2004 |
US |